The cash price for popular weight-loss medication Wegovy is dropping by 30% in U.S. on Monday, according to Novo Nordisk.

Novo Nordisk has more than enough of its Wegovy weight-loss pills to support an aggressive product launch, CEO Mike Doustdar ...

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the ...

The new pricing strategy aims to attract Americans willing to purchase medications directly from Novo Nordisk, bypassing insurance.

Novo Nordisk A/S is undercutting archrival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the U.S.

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the ...